ProCE Banner Activity

ExpressPoints
PARP Inhibitor Combinations in Prostate Cancer: Expanding Treatment Options to Broader Patient Populations

Slideset Download
Download this short summary slideset from a live Webinar to review the rationale for PARP inhibitor combination therapy in prostate cancer and current clinical data in metastatic castration-resistant prostate cancer

Released: June 23, 2021

Expiration: June 22, 2022

No longer available for credit.

Share

Faculty

Wassim Abida

Wassim Abida, MD, PhD

Director of Translational Research, Prostate Cancer
Associate Member
Genitourinary Oncology Service
Memorial Sloan Kettering Cancer Center
Associate Professor of Medicine
Weill Cornell Medical College
New York, New York

Joaquin Mateo

Joaquin Mateo, MD, PhD

Medical Oncology Department
Vall d’Hebron University Hospital
Group Leader
Vall d’Hebron Institute of Oncology
Barcelona, Spain

Charles Ryan

Charles Ryan, MD

Associate Clinical Professor
Department of Medicine Hematology/Oncology
University of California, San Francisco
San Francisco, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Merck Sharp & Dohme Corp.

Pfizer, Inc.

Faculty Disclosure

Primary Author

Wassim Abida, MD, PhD

Director of Translational Research, Prostate Cancer
Associate Member
Genitourinary Oncology Service
Memorial Sloan Kettering Cancer Center
Associate Professor of Medicine
Weill Cornell Medical College
New York, New York

Joaquin Mateo, MD, PhD

Medical Oncology Department
Vall d’Hebron University Hospital
Group Leader
Vall d’Hebron Institute of Oncology
Barcelona, Spain

Charles Ryan, MD

Associate Clinical Professor
Department of Medicine Hematology/Oncology
University of California, San Francisco
San Francisco, California